Elsevier

Lung Cancer

Volume 63, Issue 1, January 2009, Pages 83-87
Lung Cancer

Retrospective study of efficacy and toxicity on patients older than 70 years within a randomized clinical trial of two cisplatin-based combinations in patients with small-cell lung cancer

https://doi.org/10.1016/j.lungcan.2008.04.015Get rights and content

Summary

A retrospective analysis based on the Spanish Lung Cancer Group (SLCG) clinical trial of high-dose epirubicin/cisplatin in patients with small-cell lung cancer (SCLC) was performed. Patients younger than 70 years vs. older than 70 years old were analyzed to evaluate the influence of age on response to treatment, toxicity, time to progression (TTP) and overall survival (OS) of the chemotherapy schedule.

Three hundred and thirty eight patients <70 years and sixty-four >70 years, were analyzed. Objective responses were similar in both groups. In patients less than 70 years higher TTP (36 weeks vs. 32 weeks) and OS (47 weeks vs. 42 weeks) were seen, attributable to the improved results observed in the subgroup of patients with limited disease (LD). No significant differences were observed when toxicity profile of both groups was compared, except for a higher rate of febrile neutropenia observed in the elderly group with extensive disease (4.6% vs. 8.8%, p = 0.01). In the subgroup of patients with LD, elderly patients received less total cisplatin dose (401 vs. 508 mg/m2, p = 0.01) although less treatment delays were reported (10 days vs. 15 days, p = 0.05).

Age was likely to be a negative prognostic factor for OS of elderly patients with LD. It also seemed to be related to a greater dose reduction, which may explain that toxic episodes and delays occurred more frequently in the younger patients receiving the full scheduled dose. However, the definitive reason to explain this could not be established due to the characteristics of our analysis.

Introduction

Lung cancer is the first cause of death due to cancer in developed countries. In more than 50% of the cases it is diagnosed in patients older than 65 years and approximately 30% in older than 70. Small-cell lung cancer (SCLC) subtype nearly represents the 20% of all cases [1]. Besides it seems to be more frequent in patients older than 65 years. Additional factors, such as the increase of life expectancy and proportion of smoking women, have lead day after day to a higher number of SCLC elderly patients that require treatment [2].

Since an increase of the response rate and survival of SCLC patients was shown with poly-chemotherapy in the 70s, it became the standard treatment. Although no confirmatory randomized trials are available, it has been historically considered that chemotherapy tolerability may be worse in the elderly patients. This belief has lead to the use of less aggressive diagnostic procedures and treatments, frequently using non-properly validated schedules or doses that are suboptimal. It is also noteworthy that elderly patients have frequently been excluded from clinical trials.

As chemotherapy clearly provides a benefit in terms of symptomatic control and shows high response rates and significant survival increase in SCLC it is important to confirm the efficacy and tolerability of chemotherapy that is being used in the elderly population with this diagnosis. In this regard it is important to assume that aging induces significant changes in body composition, metabolism and hepatic, renal, and bone-marrow dysfunctions which have a negative impact on chemotherapy toxicity [3].

The Spanish Lung Cancer Group (SLCG) conducted a clinical trial comparing the standard chemotherapy regimen, cisplatin (P) plus etoposide (E), with the combination of high-dose epirubicin (Ep) plus cisplatin [4]. Four-hundred and two patients were enrolled, and no significant differences regarding activity, time to progression (TTP) and survival were observed. Lesser haematological toxicity was seen in the Ep arm, and this schedule could be considered then as an effective alternative for SCLC treatment, at least for extended disease patients. With the patients included in both treatment arms of this trial, a retrospective study to evaluate differences concerning efficacy, toxicity, time to progression and overall survival (OS) according to age (younger vs. older than 70 years) was performed.

Section snippets

Inclusion criteria

In the SLCG original study patients with histological or cytological SCLC diagnosis, at least one bidimensionally measurable lesion, aged between 18 and 75 years, expectancy of life more than 3 months and Karnofsky PS greater than 60%, were included. Other inclusion criteria were: adequate liver, renal and bone-marrow function. Radiotherapy was accepted for urgent cases in which the irradiated area did not include target lesions. Patients with symptomatic brain metastases previously treated

Results

In the original SLCG study no significant differences were observed between both treatment arms regarding overall treatment response, time to progression and overall survival when the 402 patients analyzed. In addition, significant differences were not observed between the toxicity profile of both schedules, except for grade 3–4 neutropenia that was more frequent in the EP arm (59.8% vs. 48%; p = 0.002).

Discussion

Theoretically, elderly patients should have worse tolerability to chemotherapy due to organ function impairment related to age and concomitant diseases. There seems to be a trend towards simplified staging work-up and suboptimal treatments without scientific data supporting these practices, particularly the lower chemotherapy benefit in these patients [3]. In most of the clinical trials reported, both in SCLC and also in other tumours, elderly patients are routinely excluded [7], [8], [9]. In

Conflict of interest

None declared.

References (16)

There are more references available in the full text version of this article.

Cited by (12)

  • The prognostic value of the simplified comorbidity score in the treatment of small cell lung carcinoma

    2011, Journal of Thoracic Oncology
    Citation Excerpt :

    The cutoff point at which the patient is considered to have a high comorbidity score was set at 9 for the SCS and at 2 for the CCIS.15–17 The patients were divided into two groups: ≤70 years and less than 70 years according to previous elderly specific analyses for oncology patients.16,22–25 Anemia was defined as hemoglobin level less than 12.11

View all citing articles on Scopus
View full text